Drug intelligence / Profile preview

LY3002815

Development stage: Discontinued
Lead developer: Eli Lilly
Modality: Small Molecules
Administration: Intravenous

Overview

LY3002815 is an investigational small molecule drug developed by Eli Lilly for the treatment of Alzheimer's disease. It functions as a beta-secretase 1 (BACE1) inhibitor, targeting the beta amyloid A4 protein precursor (APP), with the aim of reducing amyloid plaque buildup in the brain—a hallmark of Alzheimer’s pathology. The drug was administered intravenously and underwent Phase 1 clinical trials to evaluate its safety, tolerability, and pharmacokinetics in healthy volunteers. Development was ultimately discontinued after early-phase studies[1][2][3][4].

Targets

BACE1 (Beta-site APP-cleaving enzyme 1)

Beyond the preview

Go deeper on LY3002815.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LY3002815.

Explore the full profile